Hemic and Lymphatic Diseases

593 trials 238 recruiting

Filter these 593 trials by phase, country and sponsor.

Open in Search →

Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults. Ended

2024-515286-34-00 Healthy Volunteer 1 2025-03-06
HOVON 172 MF: Study on tasquinimod treatment in patients with myelofibrosis Ended

2024-511565-11-00 Myelofibrosis 9 2025-02-12
PENTALLO (PENTAglobin in Acute Leukemia and ALLOgeneic transplants) Ended

2024-518940-19-02 Acute Myeloid Leukemia (AML) 4 2025-01-28
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination with Intravenously… Ended

2024-512147-23-00 Chronic Lymphocytic Leukemia 10 2024-11-21
A Patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: RODEO study Ended

2024-516511-24-00 Chronic myeloid leukaemia 11 2024-11-14
Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018 Ended

2022-501457-37-00 Myeloid Leukemia in Children with Down Syndrome 5 2024-10-28
Clinical trial with Mosunetuzumab and Zanubrutinib in patients with relapsed/refractory follicular lymphoma Ended

2023-506049-52-00 Follicular lymphoma 4 2024-10-28
Study to treat adult patients with Very High-Risk T-cell Acute Lymphoblastic Leukemia (ALL) with Daratumumab in addition to the National ALL… Ended

2024-511627-34-00 Very High-Risk T-Lineage Acute Lymphoblastic Leukemia ( 4 2024-10-17
A Study to Assess the Efficacy and Safety of Golcadomide and Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lympho… Ended

2024-511304-16-00 Newly Diagnosed Advanced Stage Follicular Lymphoma 4 2024-10-10
Frontline Asciminib combination in chronic phase CML Ended

2024-516212-24-00 Chronic Myeloid Leukemia 4 2024-10-08
Long-term Follow-up Study of Male Adults with Hemophilia B Previously Treated with Etranacogene Dezaparvovec (CSL222) Ended

2023-503765-37-00 Hemophilia B 10 2024-09-30
First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in… Ended

2022-502808-72-00 Chronic Lymphocytic Leukemia 4 2024-09-11
Topical tacrolimus for the amelioration of breast cancer-related lymphedema: a randomized, double-blind, placebo-controlled phase II/III tri… Ended

2023-503644-13-00 Breast cancer-related lymphedema 5 2024-09-09
A study to investigate long-term follow-up in subjects who received BMN 270 in a prior BioMarin Clinical Trial with hemophilia A Ended

2023-507749-27-00 Hemophilia A 6 2024-08-16
PREVENE : Preemptive therapy with Venetoclax for high risk CLL stage A patients, a phase II trial of the FILO Ended

2024-513718-37-00 IGHV unmutated patients with high-risk stage A CLL feat 4 2024-08-01
A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High-… Ended

2023-510178-15-00 High-risk Large B-cell Lymphoma 5 2024-07-31
A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T) Ended

2024-512747-23-00 Transfusion-Dependent Alpha- or Beta-Thalassemia 5 2024-07-30
A phase II, open-label, multicenter study of orally administered RVU120 for the treatment of anemia in patients with lower-risk myelodysplas… Ended

2023-509947-29-00 Anemia in patients with very low, low or intermediate r 4 2024-07-18
An Open-Label Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of OMS906 in Patients with Paroxysmal Nocturnal Hemoglobinur… Ended

2023-507413-10-00 Paroxysmal Nocturnal Hemoglobinuria (PNH) 4 2024-07-16
An intensive program with quadruplet induction and consolidation plus tandem autologous stem cell transplantation in Newly Diagnosed High Ri… Ended

2023-509383-15-00 Multiple Myeloma 4 2024-07-05
TALTEC: A phase II study measuring MRD negativity after bispecific T-cell redirectors TALquetamab and TEClistamab consolidation as part of f… Ended

2023-508212-38-00 Multiple Myeloma 4 2024-06-11
A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapse… Ended

2023-508426-10-00 Relapsed/Refractory Multiple Myeloma 3 2024-06-03
An open label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell pr… Ended

2024-517959-12-00 Relapsed/refractory B cell precursor acute lymphoblasti 9 2024-04-11
A study to assess the safety, tolerability, uptake and efficacy of VMX-C001 in healthy volunteers. Ended

2023-507059-32-00 To restore coagulation in patients taking DOACs who are 3 2024-02-21